Omeros (NASDAQ:OMER) Stock Keeps “Overweight” Rating at Cantor Fitzgerald

Omeros (NASDAQ:OMER)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a report released on Wednesday, MarketBeat Ratings reports. They presently have a $22.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 19.37% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Omeros Stock Down 2.4%

Shares of NASDAQ OMER traded down $0.45 during mid-day trading on Wednesday, hitting $18.43. 904,948 shares of the company were exchanged, compared to its average volume of 1,650,936. The stock has a 50 day simple moving average of $18.24 and a 200-day simple moving average of $13.78. Omeros has a 1-year low of $6.24 and a 1-year high of $21.24. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of 14.40 and a beta of 2.57.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. Analysts anticipate that Omeros will post -0.37 earnings per share for the current fiscal year.

Insider Buying and Selling at Omeros

In other Omeros news, VP Peter B. Cancelmo sold 25,000 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president owned 200 shares in the company, valued at approximately $3,708. This represents a 99.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO David J. Borges sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $20.95, for a total value of $209,500.00. Following the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at $104,750. The trade was a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,906 shares of company stock valued at $1,989,705 over the last 90 days. 10.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Omeros

Large investors have recently made changes to their positions in the stock. GK Wealth Management LLC purchased a new stake in Omeros in the 3rd quarter worth approximately $65,000. Assetmark Inc. acquired a new stake in shares of Omeros during the first quarter worth $38,000. International Assets Investment Management LLC boosted its holdings in shares of Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Omeros in the fourth quarter valued at $159,000. Finally, Leonteq Securities AG purchased a new stake in Omeros in the 1st quarter valued at about $106,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.